ReP USP - Resultado da busca

Artigo de periodico
Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022) (2022)
Souza, José Diogo Ribeiro de; Pacheco, Júlia Cozar; Rossi, Giordano Novak ; Paulo, Bruno O. de; Zuardi, Antônio Waldo ; Guimarães, Francisco Silveira ; Hallak, Jaime Eduardo Cecilio ; Crippa, José Alexandre de Souza ; Santos, Rafael Guimarães dos
Source: Pharmaceutics. Unidade: FMRP
Subjects: CANABINOIDES, INTERAÇÃO DE MEDICAMENTOS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, José Diogo Ribeiro de et al. Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022). Pharmaceutics, v. 14, p. 1-14, 2022Tradução . . Disponível em: https://doi.org/10.3390/pharmaceutics14122598. Acesso em: 10 jun. 2024.
APA
Souza, J. D. R. de, Pacheco, J. C., Rossi, G. N., Paulo, B. O. de, Zuardi, A. W., Guimarães, F. S., et al. (2022). Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022). Pharmaceutics, 14, 1-14. doi:10.3390/pharmaceutics14122598
NLM
Souza JDR de, Pacheco JC, Rossi GN, Paulo BO de, Zuardi AW, Guimarães FS, Hallak JEC, Crippa JA de S, Santos RG dos. Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022) [Internet]. Pharmaceutics. 2022 ; 14 1-14.[citado 2024 jun. 10 ] Available from: https://doi.org/10.3390/pharmaceutics14122598
Vancouver
Souza JDR de, Pacheco JC, Rossi GN, Paulo BO de, Zuardi AW, Guimarães FS, Hallak JEC, Crippa JA de S, Santos RG dos. Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022) [Internet]. Pharmaceutics. 2022 ; 14 1-14.[citado 2024 jun. 10 ] Available from: https://doi.org/10.3390/pharmaceutics14122598
Artigo de periodico
What can we learn from animal models to study schizophrenia? (2022)
Crunfli, Fernanda ; Del Bel, Elaine Aparecida ; Gomes, Felipe Villela ; Teles, Caroline Brandão; Zuccoli, Giuliana S.; Chaves Filho, Adriano J. M.; Vieira, Gabriela Maciel ; Amaral, Danyelle Silva; Crippa, José Alexandre de Souza ; Pedrazzi, João Francisco Cordeiro; Macêdo, Danielle S.
Source: Advances in Experimental Medicine and Biology. Unidades: FMRP, FORP
Subjects: ESQUIZOFRENIA, MODELOS ANIMAIS, TRANSTORNOS PSICÓTICOS, NEUROTRANSMISSORES, GLUTAMATOS, PROTEÔMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CRUNFLI, Fernanda et al. What can we learn from animal models to study schizophrenia?. Advances in Experimental Medicine and Biology, v. 1400, p. 15-33, 2022Tradução . . Disponível em: https://doi.org/10.1007/978-3-030-97182-3_2. Acesso em: 10 jun. 2024.
APA
Crunfli, F., Del Bel, E. A., Gomes, F. V., Teles, C. B., Zuccoli, G. S., Chaves Filho, A. J. M., et al. (2022). What can we learn from animal models to study schizophrenia? Advances in Experimental Medicine and Biology, 1400, 15-33. doi:10.1007/978-3-030-97182-3_2
NLM
Crunfli F, Del Bel EA, Gomes FV, Teles CB, Zuccoli GS, Chaves Filho AJM, Vieira GM, Amaral DS, Crippa JA de S, Pedrazzi JFC, Macêdo DS. What can we learn from animal models to study schizophrenia? [Internet]. Advances in Experimental Medicine and Biology. 2022 ; 1400 15-33.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1007/978-3-030-97182-3_2
Vancouver
Crunfli F, Del Bel EA, Gomes FV, Teles CB, Zuccoli GS, Chaves Filho AJM, Vieira GM, Amaral DS, Crippa JA de S, Pedrazzi JFC, Macêdo DS. What can we learn from animal models to study schizophrenia? [Internet]. Advances in Experimental Medicine and Biology. 2022 ; 1400 15-33.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1007/978-3-030-97182-3_2
Artigo de periodico
Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli (2022)
Abichabki, Nathália de Lima Martins ; Zacharias, Luísa Vieira; Moreira, Natália Columbaro; Bellíssimo-Rodrigues, Fernando; Moreira, Fernanda L.; Benzi, Jhohann Richard de Lima ; Ogasawara, Tânia Mara Casare; Ferreira, Joseane Cristina; Ribeiro, Camila M.; Pavan, Fernando R.; Pereira, Leonardo Régis Leira; Brancini, Guilherme Thomaz Pereira; Braga, Gilberto Ubida Leite; Zuardi, Antonio Waldo; Hallak, Jaime Eduardo Cecilio ; Crippa, José Alexandre de Souza ; Lanchote, Vera Lucia ; Cantón, Rafael; Darini, Ana Lúcia da Costa ; Andrade, Leonardo Neves de
Source: Scientific Reports. Unidades: FMRP, FCFRP
Subjects: CANABINOIDES, REPOSICIONAMENTO DE FÁRMACOS, RESISTÊNCIA MICROBIANA ÀS DROGAS, SINERGISMO DE DROGAS, TESTES DE SENSIBILIDADE MICROBIANA, BACTÉRIAS GRAM-NEGATIVAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ABICHABKI, Nathália de Lima Martins et al. Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli. Scientific Reports, v. 12, p. 1-15, 2022Tradução . . Disponível em: https://doi.org/10.1038/s41598-022-10393-8. Acesso em: 10 jun. 2024.
APA
Abichabki, N. de L. M., Zacharias, L. V., Moreira, N. C., Bellíssimo-Rodrigues, F., Moreira, F. L., Benzi, J. R. de L., et al. (2022). Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli. Scientific Reports, 12, 1-15. doi:10.1038/s41598-022-10393-8
NLM
Abichabki N de LM, Zacharias LV, Moreira NC, Bellíssimo-Rodrigues F, Moreira FL, Benzi JR de L, Ogasawara TMC, Ferreira JC, Ribeiro CM, Pavan FR, Pereira LRL, Brancini GTP, Braga GUL, Zuardi AW, Hallak JEC, Crippa JA de S, Lanchote VL, Cantón R, Darini AL da C, Andrade LN de. Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli [Internet]. Scientific Reports. 2022 ; 12 1-15.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1038/s41598-022-10393-8
Vancouver
Abichabki N de LM, Zacharias LV, Moreira NC, Bellíssimo-Rodrigues F, Moreira FL, Benzi JR de L, Ogasawara TMC, Ferreira JC, Ribeiro CM, Pavan FR, Pereira LRL, Brancini GTP, Braga GUL, Zuardi AW, Hallak JEC, Crippa JA de S, Lanchote VL, Cantón R, Darini AL da C, Andrade LN de. Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli [Internet]. Scientific Reports. 2022 ; 12 1-15.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1038/s41598-022-10393-8
Artigo de periodico
Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze (2022)
Fabris, Débora; Carvalho, Milene Cristina de ; Brandão, Marcus Lira ; Prado, Wiliam Alves do; Zuardi, Antônio Waldo ; Crippa, José Alexandre de Souza ; Oliveira, Amanda R. de; Lovick, Thelma A.; Genaro, Karina
Source: Journal of Psychopharmacology. Unidades: FMRP, FFCLRP
Subjects: ANSIEDADE, ANTIDEPRESSIVOS, FARMACOTERAPIA, CANABINOIDES, DIFERENÇAS SEXUAIS ANIMAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FABRIS, Débora et al. Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze. Journal of Psychopharmacology, v. 36, n. 12, p. 1371-1383, 2022Tradução . . Disponível em: https://doi.org/10.1177/02698811221125440. Acesso em: 10 jun. 2024.
APA
Fabris, D., Carvalho, M. C. de, Brandão, M. L., Prado, W. A. do, Zuardi, A. W., Crippa, J. A. de S., et al. (2022). Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze. Journal of Psychopharmacology, 36( 12), 1371-1383. doi:10.1177/02698811221125440
NLM
Fabris D, Carvalho MC de, Brandão ML, Prado WA do, Zuardi AW, Crippa JA de S, Oliveira AR de, Lovick TA, Genaro K. Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze [Internet]. Journal of Psychopharmacology. 2022 ; 36( 12): 1371-1383.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1177/02698811221125440
Vancouver
Fabris D, Carvalho MC de, Brandão ML, Prado WA do, Zuardi AW, Crippa JA de S, Oliveira AR de, Lovick TA, Genaro K. Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze [Internet]. Journal of Psychopharmacology. 2022 ; 36( 12): 1371-1383.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1177/02698811221125440
Artigo de periodico
Cannabidiol induces antidepressant and anxiolytic‐like effects in experimental type-1 diabetic animals by multiple sites of action (2021)
Chaves, Yane Costa; Genaro, Karina; Crippa, José Alexandre de Souza ; Cunha, Joice Maria da; Zanoveli, Janaina Menezes
Source: Metabolic Brain Disease. Unidade: FMRP
Subjects: ANSIOLÍTICOS, ANTIDEPRESSIVOS, CANABINOIDES, DIABETES MELLITUS, FARMACOTERAPIA, SEROTONINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHAVES, Yane Costa et al. Cannabidiol induces antidepressant and anxiolytic‐like effects in experimental type-1 diabetic animals by multiple sites of action. Metabolic Brain Disease, v. 36, n. 4, p. 639-652, 2021Tradução . . Disponível em: https://doi.org/10.1007/s11011-020-00667-3. Acesso em: 10 jun. 2024.
APA
Chaves, Y. C., Genaro, K., Crippa, J. A. de S., Cunha, J. M. da, & Zanoveli, J. M. (2021). Cannabidiol induces antidepressant and anxiolytic‐like effects in experimental type-1 diabetic animals by multiple sites of action. Metabolic Brain Disease, 36( 4), 639-652. doi:10.1007/s11011-020-00667-3
NLM
Chaves YC, Genaro K, Crippa JA de S, Cunha JM da, Zanoveli JM. Cannabidiol induces antidepressant and anxiolytic‐like effects in experimental type-1 diabetic animals by multiple sites of action [Internet]. Metabolic Brain Disease. 2021 ; 36( 4): 639-652.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1007/s11011-020-00667-3
Vancouver
Chaves YC, Genaro K, Crippa JA de S, Cunha JM da, Zanoveli JM. Cannabidiol induces antidepressant and anxiolytic‐like effects in experimental type-1 diabetic animals by multiple sites of action [Internet]. Metabolic Brain Disease. 2021 ; 36( 4): 639-652.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1007/s11011-020-00667-3
Artigo de periodico
Mononitrate isosorbide as an adjunctive therapy in schizophrenia: a randomized controlled crossover trial (2021)
Guimarães, Tiago Moraes; Guimarães, Mara R. C.; Oliveira, Ícaro A. F.; Leoni, Renata Ferranti ; Santos, Antonio Carlos dos ; Dursun, Serdar M.; Crippa, José Alexandre de Souza ; Bressan, Rodrigo A.; Machado-de-Sousa, João Paulo ; Lacerda, Acioly L. T.; Hallak, Jaime Eduardo Cecilio
Source: Journal of Clinical Psychopharmacology. Unidades: FFCLRP, FMRP
Subjects: ANTIPSICÓTICOS, MÉTODO DUPLO-CEGO, FARMACOTERAPIA, ESQUIZOFRENIA, RESULTADO DE TRATAMENTO, FÁRMACOS (SISTEMA CARDIOVASCULAR)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GUIMARÃES, Tiago Moraes et al. Mononitrate isosorbide as an adjunctive therapy in schizophrenia: a randomized controlled crossover trial. Journal of Clinical Psychopharmacology, v. 41, n. 3, p. 260-266, 2021Tradução . . Disponível em: https://doi.org/10.1097/JCP.0000000000001388. Acesso em: 10 jun. 2024.
APA
Guimarães, T. M., Guimarães, M. R. C., Oliveira, Í. A. F., Leoni, R. F., Santos, A. C. dos, Dursun, S. M., et al. (2021). Mononitrate isosorbide as an adjunctive therapy in schizophrenia: a randomized controlled crossover trial. Journal of Clinical Psychopharmacology, 41( 3), 260-266. doi:10.1097/JCP.0000000000001388
NLM
Guimarães TM, Guimarães MRC, Oliveira ÍAF, Leoni RF, Santos AC dos, Dursun SM, Crippa JA de S, Bressan RA, Machado-de-Sousa JP, Lacerda ALT, Hallak JEC. Mononitrate isosorbide as an adjunctive therapy in schizophrenia: a randomized controlled crossover trial [Internet]. Journal of Clinical Psychopharmacology. 2021 ; 41( 3): 260-266.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1097/JCP.0000000000001388
Vancouver
Guimarães TM, Guimarães MRC, Oliveira ÍAF, Leoni RF, Santos AC dos, Dursun SM, Crippa JA de S, Bressan RA, Machado-de-Sousa JP, Lacerda ALT, Hallak JEC. Mononitrate isosorbide as an adjunctive therapy in schizophrenia: a randomized controlled crossover trial [Internet]. Journal of Clinical Psychopharmacology. 2021 ; 41( 3): 260-266.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1097/JCP.0000000000001388
Artigo de periodico
Cortical surface abnormalities are different depending on the stage of schizophrenia: a cross-sectional vertexwise mega-analysis of thickness, area and gyrification (2021)
Rosa, Pedro Gomes Penteado; Zugman, Andre; Cerqueira, Carlos Toledo; Serpa, Mauricio Henriques ; Duran, Fábio Luís de Souza; Zanetti, Marcus Vinicius; Bassitt, Débora Pastore; Elkis, Helio ; Crippa, José Alexandre de Souza ; Sallet, Paulo Clemente; Gattaz, Wagner Farid ; Hallak, Jaime Eduardo Cecilio ; Louzã Neto, Mario Rodrigues; Gadelha, Ary; Jackowski, Andrea Parolin; Bressan, Rodrigo Affonseca; Busatto Filho, Geraldo
Source: Schizophrenia Research. Unidades: FM, FMRP
Subjects: TRANSTORNOS PSICÓTICOS, ESQUIZOFRENIA, ANTIPSICÓTICOS, CÓRTEX CEREBRAL, DIAGNÓSTICO POR IMAGEM, ESTUDOS TRANSVERSAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROSA, Pedro Gomes Penteado et al. Cortical surface abnormalities are different depending on the stage of schizophrenia: a cross-sectional vertexwise mega-analysis of thickness, area and gyrification. Schizophrenia Research, v. 236, p. 104-114, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.schres.2021.08.011. Acesso em: 10 jun. 2024.
APA
Rosa, P. G. P., Zugman, A., Cerqueira, C. T., Serpa, M. H., Duran, F. L. de S., Zanetti, M. V., et al. (2021). Cortical surface abnormalities are different depending on the stage of schizophrenia: a cross-sectional vertexwise mega-analysis of thickness, area and gyrification. Schizophrenia Research, 236, 104-114. doi:10.1016/j.schres.2021.08.011
NLM
Rosa PGP, Zugman A, Cerqueira CT, Serpa MH, Duran FL de S, Zanetti MV, Bassitt DP, Elkis H, Crippa JA de S, Sallet PC, Gattaz WF, Hallak JEC, Louzã Neto MR, Gadelha A, Jackowski AP, Bressan RA, Busatto Filho G. Cortical surface abnormalities are different depending on the stage of schizophrenia: a cross-sectional vertexwise mega-analysis of thickness, area and gyrification [Internet]. Schizophrenia Research. 2021 ; 236 104-114.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1016/j.schres.2021.08.011
Vancouver
Rosa PGP, Zugman A, Cerqueira CT, Serpa MH, Duran FL de S, Zanetti MV, Bassitt DP, Elkis H, Crippa JA de S, Sallet PC, Gattaz WF, Hallak JEC, Louzã Neto MR, Gadelha A, Jackowski AP, Bressan RA, Busatto Filho G. Cortical surface abnormalities are different depending on the stage of schizophrenia: a cross-sectional vertexwise mega-analysis of thickness, area and gyrification [Internet]. Schizophrenia Research. 2021 ; 236 104-114.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1016/j.schres.2021.08.011
Artigo de periodico
Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum (2021)
Pedrazzi, João Francisco Cordeiro; Sales, Amanda Juliana; Guimarães, Francisco Silveira ; Joca, Sâmia Regiane Lourenço ; Crippa, José Alexandre de Souza ; Del Bel, Elaine Aparecida
Source: Progress in Neuro-Psychopharmacology and Biological Psychiatry. Unidades: FMRP, FCFRP, FORP
Subjects: ANFETAMINAS, ANTIPSICÓTICOS, COMPORTAMENTO ANIMAL, CANABINOIDES, METILAÇÃO DE DNA, CÓRTEX PRÉ-FRONTAL, ESQUIZOFRENIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PEDRAZZI, João Francisco Cordeiro et al. Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum. Progress in Neuro-Psychopharmacology and Biological Psychiatry, v. 111, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.pnpbp.2021.110352. Acesso em: 10 jun. 2024.
APA
Pedrazzi, J. F. C., Sales, A. J., Guimarães, F. S., Joca, S. R. L., Crippa, J. A. de S., & Del Bel, E. A. (2021). Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 111. doi:10.1016/j.pnpbp.2021.110352
NLM
Pedrazzi JFC, Sales AJ, Guimarães FS, Joca SRL, Crippa JA de S, Del Bel EA. Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum [Internet]. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2021 ; 111[citado 2024 jun. 10 ] Available from: https://doi.org/10.1016/j.pnpbp.2021.110352
Vancouver
Pedrazzi JFC, Sales AJ, Guimarães FS, Joca SRL, Crippa JA de S, Del Bel EA. Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum [Internet]. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2021 ; 111[citado 2024 jun. 10 ] Available from: https://doi.org/10.1016/j.pnpbp.2021.110352
Artigo de periodico
Endocannabinoid levels in patients with Parkinson’s disease with and without levodopa-induced dyskinesias (2020)
Marchioni, Camila; Santos-Lobato, Bruno Lopes; Queiroz, Maria Eugênia Costa ; Crippa, José Alexandre de Souza ; Tumas, Vitor
Source: Journal of Neural Transmission. Unidades: FFCLRP, FMRP, FCFRP
Subjects: DOENÇA DE PARKINSON, DISCINESIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MARCHIONI, Camila et al. Endocannabinoid levels in patients with Parkinson’s disease with and without levodopa-induced dyskinesias. Journal of Neural Transmission, v. 127, n. 10, p. 1359-1367, 2020Tradução . . Disponível em: https://doi.org/10.1007/s00702-020-02240-9. Acesso em: 10 jun. 2024.
APA
Marchioni, C., Santos-Lobato, B. L., Queiroz, M. E. C., Crippa, J. A. de S., & Tumas, V. (2020). Endocannabinoid levels in patients with Parkinson’s disease with and without levodopa-induced dyskinesias. Journal of Neural Transmission, 127( 10), 1359-1367. doi:10.1007/s00702-020-02240-9
NLM
Marchioni C, Santos-Lobato BL, Queiroz MEC, Crippa JA de S, Tumas V. Endocannabinoid levels in patients with Parkinson’s disease with and without levodopa-induced dyskinesias [Internet]. Journal of Neural Transmission. 2020 ; 127( 10): 1359-1367.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1007/s00702-020-02240-9
Vancouver
Marchioni C, Santos-Lobato BL, Queiroz MEC, Crippa JA de S, Tumas V. Endocannabinoid levels in patients with Parkinson’s disease with and without levodopa-induced dyskinesias [Internet]. Journal of Neural Transmission. 2020 ; 127( 10): 1359-1367.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1007/s00702-020-02240-9
Artigo de periodico
DMH-CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF-kB activity dependent on A2A receptor (2019)
Silva, Rangel Leal ; Silveira, Gabriela Tosta; Wanderlei, Carlos W.; Cecilio, Nerry Tatiana ; Maganin, Alexandre Gomes de Macedo ; Franchin, Marcelo; Marques, Lucas Maciel Mauriz ; Lopes, Norberto Peporine ; Crippa, José Alexandre de Souza ; Guimarães, Francisco Silveira; Alves-Filho, José Carlos Farias ; Cunha, Fernando de Queiroz ; Cunha, Thiago Mattar
Source: Toxicology and Applied Pharmacology. Unidades: FCFRP, FMRP
Subjects: CANABINOIDES, MACRÓFAGOS, ANTI-INFLAMATÓRIOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Rangel Leal et al. DMH-CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF-kB activity dependent on A2A receptor. Toxicology and Applied Pharmacology, v. 368, p. 63-71, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.taap.2019.02.011. Acesso em: 10 jun. 2024.
APA
Silva, R. L., Silveira, G. T., Wanderlei, C. W., Cecilio, N. T., Maganin, A. G. de M., Franchin, M., et al. (2019). DMH-CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF-kB activity dependent on A2A receptor. Toxicology and Applied Pharmacology, 368, 63-71. doi:10.1016/j.taap.2019.02.011
NLM
Silva RL, Silveira GT, Wanderlei CW, Cecilio NT, Maganin AG de M, Franchin M, Marques LMM, Lopes NP, Crippa JA de S, Guimarães FS, Alves-Filho JCF, Cunha F de Q, Cunha TM. DMH-CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF-kB activity dependent on A2A receptor [Internet]. Toxicology and Applied Pharmacology. 2019 ; 368 63-71.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1016/j.taap.2019.02.011
Vancouver
Silva RL, Silveira GT, Wanderlei CW, Cecilio NT, Maganin AG de M, Franchin M, Marques LMM, Lopes NP, Crippa JA de S, Guimarães FS, Alves-Filho JCF, Cunha F de Q, Cunha TM. DMH-CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF-kB activity dependent on A2A receptor [Internet]. Toxicology and Applied Pharmacology. 2019 ; 368 63-71.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1016/j.taap.2019.02.011
Artigo de periodico
Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors (2019)
Jesus, Carlos Henrique Alves; Redivo, Daiany Darlly Bello; Gasparin, Aléxia Thamara; Sotomaior, Bruna Bittencourt; Carvalho, Milene Cristina de ; Genaro, Karina ; Zuardi, Antônio Waldo ; Hallak, Jaime Eduardo Cecilio ; Crippa, José Alexandre de Souza ; Zanoveli, Janaina Menezes; Cunha, Joice Maria da
Source: Brain Research. Unidade: FMRP
Subjects: DIABETES MELLITUS, NEUROPATIAS DIABÉTICAS, CANABINOIDES, RECEPTORES DE DROGA, SEROTONINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
JESUS, Carlos Henrique Alves et al. Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors. Brain Research, v. 1715, p. 156-164, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.brainres.2019.03.014. Acesso em: 10 jun. 2024.
APA
Jesus, C. H. A., Redivo, D. D. B., Gasparin, A. T., Sotomaior, B. B., Carvalho, M. C. de, Genaro, K., et al. (2019). Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors. Brain Research, 1715, 156-164. doi:10.1016/j.brainres.2019.03.014
NLM
Jesus CHA, Redivo DDB, Gasparin AT, Sotomaior BB, Carvalho MC de, Genaro K, Zuardi AW, Hallak JEC, Crippa JA de S, Zanoveli JM, Cunha JM da. Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors [Internet]. Brain Research. 2019 ; 1715 156-164.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1016/j.brainres.2019.03.014
Vancouver
Jesus CHA, Redivo DDB, Gasparin AT, Sotomaior BB, Carvalho MC de, Genaro K, Zuardi AW, Hallak JEC, Crippa JA de S, Zanoveli JM, Cunha JM da. Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors [Internet]. Brain Research. 2019 ; 1715 156-164.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1016/j.brainres.2019.03.014
Artigo de periodico
Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms? (2019)
Crippa, José Alexandre de Souza ; Hallak, Jaime Eduardo Cecilio ; Zuardi, Antônio Waldo ; Guimarães, Francisco Silveira ; Tumas, Vitor ; Santos, Rafael Guimarães dos
Source: European Archives of Psychiatry and Clinical Neuroscience. Unidade: FMRP
Subjects: DOENÇA DE PARKINSON, CANABINOIDES, SINTOMAS E PATOLOGIA GERAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CRIPPA, José Alexandre de Souza et al. Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?. European Archives of Psychiatry and Clinical Neuroscience, v. 269, n. 1, p. 121-133, 2019Tradução . . Disponível em: https://doi.org/10.1007/s00406-019-00982-6. Acesso em: 10 jun. 2024.
APA
Crippa, J. A. de S., Hallak, J. E. C., Zuardi, A. W., Guimarães, F. S., Tumas, V., & Santos, R. G. dos. (2019). Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms? European Archives of Psychiatry and Clinical Neuroscience, 269( 1), 121-133. doi:10.1007/s00406-019-00982-6
NLM
Crippa JA de S, Hallak JEC, Zuardi AW, Guimarães FS, Tumas V, Santos RG dos. Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms? [Internet]. European Archives of Psychiatry and Clinical Neuroscience. 2019 ; 269( 1): 121-133.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1007/s00406-019-00982-6
Vancouver
Crippa JA de S, Hallak JEC, Zuardi AW, Guimarães FS, Tumas V, Santos RG dos. Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms? [Internet]. European Archives of Psychiatry and Clinical Neuroscience. 2019 ; 269( 1): 121-133.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1007/s00406-019-00982-6
Artigo de periodico
Modulation of the endocannabinoid and oxytocinergic systems as a potential treatment approach for social anxiety disorder (2019)
Dos Santos, Rafael Guimarães dos ; Osório, Flávia de Lima ; Martin-Santos, Rocio ; Zuardi, Antônio Waldo ; Hallak, Jaime Eduardo Cecilio ; Crippa, José Alexandre de Souza
Source: CNS Drugs. Unidade: FMRP
Subjects: TRANSTORNOS DA ANSIEDADE, ANSIEDADE SOCIAL, CANABINOIDES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOS SANTOS, Rafael Guimarães dos et al. Modulation of the endocannabinoid and oxytocinergic systems as a potential treatment approach for social anxiety disorder. CNS Drugs, v. 33, n. 10, p. 1031-1038, 2019Tradução . . Disponível em: https://doi.org/10.1007/s40263-019-00669-5. Acesso em: 10 jun. 2024.
APA
Dos Santos, R. G. dos, Osório, F. de L., Martin-Santos, R., Zuardi, A. W., Hallak, J. E. C., & Crippa, J. A. de S. (2019). Modulation of the endocannabinoid and oxytocinergic systems as a potential treatment approach for social anxiety disorder. CNS Drugs, 33( 10), 1031-1038. doi:10.1007/s40263-019-00669-5
NLM
Dos Santos RG dos, Osório F de L, Martin-Santos R, Zuardi AW, Hallak JEC, Crippa JA de S. Modulation of the endocannabinoid and oxytocinergic systems as a potential treatment approach for social anxiety disorder [Internet]. CNS Drugs. 2019 ; 33( 10): 1031-1038.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1007/s40263-019-00669-5
Vancouver
Dos Santos RG dos, Osório F de L, Martin-Santos R, Zuardi AW, Hallak JEC, Crippa JA de S. Modulation of the endocannabinoid and oxytocinergic systems as a potential treatment approach for social anxiety disorder [Internet]. CNS Drugs. 2019 ; 33( 10): 1031-1038.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1007/s40263-019-00669-5
Artigo de periodico
Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system (2018)
Schonhofen, Patrícia; Bristot, Ivi Juliana; Crippa, José Alexandre de Souza; Hallak, Jaime Eduardo Cecílio; Zuardi, Antônio Waldo; Parsons, Richard B.; Klamt, Fábio
Source: CNS Drugs. Unidade: FMRP
Subjects: CANNABIS, TERAPÊUTICA MÉDICA, SISTEMA NERVOSO CENTRAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SCHONHOFEN, Patrícia et al. Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system. CNS Drugs, v. 32, n. 8, p. 697-712, 2018Tradução . . Disponível em: https://doi.org/10.1007/s40263-018-0550-4. Acesso em: 10 jun. 2024.
APA
Schonhofen, P., Bristot, I. J., Crippa, J. A. de S., Hallak, J. E. C., Zuardi, A. W., Parsons, R. B., & Klamt, F. (2018). Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system. CNS Drugs, 32( 8), 697-712. doi:10.1007/s40263-018-0550-4
NLM
Schonhofen P, Bristot IJ, Crippa JA de S, Hallak JEC, Zuardi AW, Parsons RB, Klamt F. Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system [Internet]. CNS Drugs. 2018 ; 32( 8): 697-712.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1007/s40263-018-0550-4
Vancouver
Schonhofen P, Bristot IJ, Crippa JA de S, Hallak JEC, Zuardi AW, Parsons RB, Klamt F. Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system [Internet]. CNS Drugs. 2018 ; 32( 8): 697-712.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1007/s40263-018-0550-4
Artigo de periodico
Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age (2018)
Crippa, José Alexandre de Souza; Guimarães, Francisco Silveira; Campos, Alline Cristina de; Zuardi, Antônio Waldo
Source: Frontiers in Immunology. Unidade: FMRP
Subjects: CANABINOIDES, NEUROPSIQUIATRIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CRIPPA, José Alexandre de Souza et al. Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Frontiers in Immunology, v. 9, 2018Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2018.02009. Acesso em: 10 jun. 2024.
APA
Crippa, J. A. de S., Guimarães, F. S., Campos, A. C. de, & Zuardi, A. W. (2018). Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Frontiers in Immunology, 9. doi:10.3389/fimmu.2018.02009
NLM
Crippa JA de S, Guimarães FS, Campos AC de, Zuardi AW. Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age [Internet]. Frontiers in Immunology. 2018 ; 9[citado 2024 jun. 10 ] Available from: https://doi.org/10.3389/fimmu.2018.02009
Vancouver
Crippa JA de S, Guimarães FS, Campos AC de, Zuardi AW. Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age [Internet]. Frontiers in Immunology. 2018 ; 9[citado 2024 jun. 10 ] Available from: https://doi.org/10.3389/fimmu.2018.02009
Artigo de periodico
Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: reversal by cannabidiol (2018)
Silva, Vanessa Kappel da; Freitas, Betânia Souza de; Dornelles, Victória Campos; Kist, Luiza Wilges; Bogo, Maurício Reis; Silva, Milena Carvalho; Streck, Emílio Luiz; Hallak, Jaime Eduardo Cecílio; Zuardi, Antônio Waldo; Crippa, José Alexandre de Souza; Schröder, Nadja
Source: Brain Research Bulletin. Unidade: FMRP
Subjects: CANABINOIDES, MITOCÔNDRIAS, DNA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Vanessa Kappel da et al. Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: reversal by cannabidiol. Brain Research Bulletin, v. 139, p. 1-8, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.brainresbull.2018.01.014. Acesso em: 10 jun. 2024.
APA
Silva, V. K. da, Freitas, B. S. de, Dornelles, V. C., Kist, L. W., Bogo, M. R., Silva, M. C., et al. (2018). Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: reversal by cannabidiol. Brain Research Bulletin, 139, 1-8. doi:10.1016/j.brainresbull.2018.01.014
NLM
Silva VK da, Freitas BS de, Dornelles VC, Kist LW, Bogo MR, Silva MC, Streck EL, Hallak JEC, Zuardi AW, Crippa JA de S, Schröder N. Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: reversal by cannabidiol [Internet]. Brain Research Bulletin. 2018 ; 139 1-8.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1016/j.brainresbull.2018.01.014
Vancouver
Silva VK da, Freitas BS de, Dornelles VC, Kist LW, Bogo MR, Silva MC, Streck EL, Hallak JEC, Zuardi AW, Crippa JA de S, Schröder N. Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: reversal by cannabidiol [Internet]. Brain Research Bulletin. 2018 ; 139 1-8.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1016/j.brainresbull.2018.01.014
Artigo de periodico
Maternal administration of cannabidiol promotes an anti-inflammatory effect on the intestinal wall in a gastroschisis rat model (2018)
Callejas, G. H.; Figueira, R. L.; Gonçalves, F. L. L.; Volpe, F. A. P.; Zuardi, Antônio Waldo; Crippa, José Alexandre de Souza; Hallak, Jaime Eduardo Cecílio; Sbragia, Lourenço
Source: Brazilian Journal of Medical and Biological Research. Unidade: FMRP
Subjects: CANABINOIDES, DIAGNÓSTICO PRÉ-NATAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CALLEJAS, G. H. et al. Maternal administration of cannabidiol promotes an anti-inflammatory effect on the intestinal wall in a gastroschisis rat model. Brazilian Journal of Medical and Biological Research, v. 51, n. 5, 2018Tradução . . Disponível em: https://doi.org/10.1590/1414-431x20177132. Acesso em: 10 jun. 2024.
APA
Callejas, G. H., Figueira, R. L., Gonçalves, F. L. L., Volpe, F. A. P., Zuardi, A. W., Crippa, J. A. de S., et al. (2018). Maternal administration of cannabidiol promotes an anti-inflammatory effect on the intestinal wall in a gastroschisis rat model. Brazilian Journal of Medical and Biological Research, 51( 5). doi:10.1590/1414-431x20177132
NLM
Callejas GH, Figueira RL, Gonçalves FLL, Volpe FAP, Zuardi AW, Crippa JA de S, Hallak JEC, Sbragia L. Maternal administration of cannabidiol promotes an anti-inflammatory effect on the intestinal wall in a gastroschisis rat model [Internet]. Brazilian Journal of Medical and Biological Research. 2018 ; 51( 5):[citado 2024 jun. 10 ] Available from: https://doi.org/10.1590/1414-431x20177132
Vancouver
Callejas GH, Figueira RL, Gonçalves FLL, Volpe FAP, Zuardi AW, Crippa JA de S, Hallak JEC, Sbragia L. Maternal administration of cannabidiol promotes an anti-inflammatory effect on the intestinal wall in a gastroschisis rat model [Internet]. Brazilian Journal of Medical and Biological Research. 2018 ; 51( 5):[citado 2024 jun. 10 ] Available from: https://doi.org/10.1590/1414-431x20177132
Artigo de periodico
Borderline personality disorder and bias in the recognition of facial expressions of emotion: a pathway to understand the psychopathology (2018)
Ferreira, Gabriela C. S.; Sanches, Rafael Faria; Crippa, José Alexandre de Souza; Mello, Marcelo Feijó de; Osório, Flávia de Lima
Source: Archives of Clinical Psychiatry. Unidade: FMRP
Subjects: PSIQUIATRIA, FACE, EMOÇÕES, PERSONALIDADE, PSICOPATOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERREIRA, Gabriela C. S. et al. Borderline personality disorder and bias in the recognition of facial expressions of emotion: a pathway to understand the psychopathology. Archives of Clinical Psychiatry, v. 45, n. 1, p. 7-11, 2018Tradução . . Disponível em: https://doi.org/10.1590/0101-60830000000146. Acesso em: 10 jun. 2024.
APA
Ferreira, G. C. S., Sanches, R. F., Crippa, J. A. de S., Mello, M. F. de, & Osório, F. de L. (2018). Borderline personality disorder and bias in the recognition of facial expressions of emotion: a pathway to understand the psychopathology. Archives of Clinical Psychiatry, 45( 1), 7-11. doi:10.1590/0101-60830000000146
NLM
Ferreira GCS, Sanches RF, Crippa JA de S, Mello MF de, Osório F de L. Borderline personality disorder and bias in the recognition of facial expressions of emotion: a pathway to understand the psychopathology [Internet]. Archives of Clinical Psychiatry. 2018 ; 45( 1): 7-11.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1590/0101-60830000000146
Vancouver
Ferreira GCS, Sanches RF, Crippa JA de S, Mello MF de, Osório F de L. Borderline personality disorder and bias in the recognition of facial expressions of emotion: a pathway to understand the psychopathology [Internet]. Archives of Clinical Psychiatry. 2018 ; 45( 1): 7-11.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1590/0101-60830000000146
Artigo de periodico
Cross-cultural adaptation and psychometric assessment of a Brazilian-Portuguese version of the Resident Questionnaire (2018)
Lima, Karina Pereira; Rodrigues, Ana Paula Casagrande Silva; Marucci, Flávia Andressa Farnocchi; Osório, Flávia de Lima; Crippa, José Alexandre de Souza; Loureiro, Sonia Regina
Source: PLOS ONE. Unidade: FMRP
Subjects: QUESTIONÁRIOS, PSICOMETRIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Karina Pereira et al. Cross-cultural adaptation and psychometric assessment of a Brazilian-Portuguese version of the Resident Questionnaire. PLOS ONE, v. 13, n. 9, p. e0203531, 2018Tradução . . Disponível em: https://doi.org/10.1371/journal.pone.0203531. Acesso em: 10 jun. 2024.
APA
Lima, K. P., Rodrigues, A. P. C. S., Marucci, F. A. F., Osório, F. de L., Crippa, J. A. de S., & Loureiro, S. R. (2018). Cross-cultural adaptation and psychometric assessment of a Brazilian-Portuguese version of the Resident Questionnaire. PLOS ONE, 13( 9), e0203531. doi:10.1371/journal.pone.0203531
NLM
Lima KP, Rodrigues APCS, Marucci FAF, Osório F de L, Crippa JA de S, Loureiro SR. Cross-cultural adaptation and psychometric assessment of a Brazilian-Portuguese version of the Resident Questionnaire [Internet]. PLOS ONE. 2018 ; 13( 9): e0203531.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1371/journal.pone.0203531
Vancouver
Lima KP, Rodrigues APCS, Marucci FAF, Osório F de L, Crippa JA de S, Loureiro SR. Cross-cultural adaptation and psychometric assessment of a Brazilian-Portuguese version of the Resident Questionnaire [Internet]. PLOS ONE. 2018 ; 13( 9): e0203531.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1371/journal.pone.0203531
Artigo de periodico
Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload (2018)
Silva, Vanessa Kappel da; Freitas, Betânia Souza de; Garcia, Rebeca Carvalho Lacerda; Monteiro, Ricardo Tavares; Hallak, Jaime Eduardo Cecílio ; Zuardi, Antônio Waldo; Crippa, José Alexandre de Souza; Schröder, Nadja
Source: Translational Psychiatry. Unidade: FMRP
Subjects: CANABINOIDES, COGNIÇÃO, FERRO, MEMÓRIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Vanessa Kappel da et al. Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload. Translational Psychiatry, v. 8, n. 1, 2018Tradução . . Disponível em: https://doi.org/10.1038/s41398-018-0232-5. Acesso em: 10 jun. 2024.
APA
Silva, V. K. da, Freitas, B. S. de, Garcia, R. C. L., Monteiro, R. T., Hallak, J. E. C., Zuardi, A. W., et al. (2018). Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload. Translational Psychiatry, 8( 1). doi:10.1038/s41398-018-0232-5
NLM
Silva VK da, Freitas BS de, Garcia RCL, Monteiro RT, Hallak JEC, Zuardi AW, Crippa JA de S, Schröder N. Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload [Internet]. Translational Psychiatry. 2018 ; 8( 1):[citado 2024 jun. 10 ] Available from: https://doi.org/10.1038/s41398-018-0232-5
Vancouver
Silva VK da, Freitas BS de, Garcia RCL, Monteiro RT, Hallak JEC, Zuardi AW, Crippa JA de S, Schröder N. Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload [Internet]. Translational Psychiatry. 2018 ; 8( 1):[citado 2024 jun. 10 ] Available from: https://doi.org/10.1038/s41398-018-0232-5

USP Schools

ReP

Filtros

USP Schools

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Countries/Territories

Funding Agencies

Indexado em

Normalized affiliation

Non normalized affiliation

Countries of institutions of collaboration